Alternating two screening modalities pays off forwomen with high genetic likelihood of breast cancerAlternating MRI with mammographyevery six months picks up breastcancers missed when mammographyis performed alone for high-riskwomen.
Alternating two screening modalities pays off for women with high genetic likelihood of breast cancer Alternating MRI with mammography every six months picks up breast cancers missed when mammography is performed alone for high-risk women.
The two screening modalities are alternated in many special programs for women with confirmed BRCA1 and BRCA2 genetic mutations giving them an exceptionally high risk for developing breast cancer. Until now, no one has established a scientific basis for adopting the tactic.
Dr. Huong Le-Petross, an assistant professor of radiology at M.D. Anderson Cancer Center in Houston, reviewed the medical records of 334 consecutive women. Of those patients, 26% (86) underwent annual screening mammography and MRI, alternating every six months. The rest underwent prophylactic mastectomies or were treated with chemoprevention.
Overall, the researchers identified nine cancers in seven women with screening MRI: six invasive ductal, one invasive lobular, and two ductal carcinomas in situ.
Four of these cancers were identified only with MRI, four were identified with both MRI and mammography, and one was missed by both modalities before diagnosis after prophylactic mastectomy.
“The global picture is that MRI can pick up cancers that mammography cannot,” Le-Petross said.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.